Neuropsychological Integrative Ontology

Last uploaded: December 23, 2020
Preferred Name

Parkinsons disease
Synonyms
Definitions

belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. (A disease characterized as a progressive motor disability manifested by tremors, shaking, muscular rigidity, and lack of postural reflexes. (PSY) * A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) (MSH) * progressive, degenerative disorder of the nervous system characterized by tremors, rigidity, bradykinesia, postural instability, and gait abnormalities; caused by a loss of neurons and a decrease of dopamine in the basal ganglia. (CSP) ) Parkinsons disease is a neurological disease where abnormal movement [tremor, rigidity, bradykinesia, postural instability] occurs resulting in a movement disorder caused by neurodegeneration as a result of death of dopaminergic cells in the substantia nigra. ---------- Parkinsons disease is a degenerative disorder of the central nervous system. It results from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain; the cause of cell-death is unknown. Early in the course of the disease, the most obvious symptoms are movement-related, including shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, cognitive and behavioural problems may arise, with dementia commonly occurring in the advanced stages of the disease. Other symptoms include sensory, sleep and emotional problems. PD is more common in the elderly with most cases occurring after the age of 50. The main motor symptoms are collectively called parkinsonism, or a "parkinsonian syndrome". Parkinson's disease is often defined as a parkinsonian syndrome that is idiopathic (having no known cause), although some atypical cases have a genetic origin. Many risk and protective factors have been investigated: the clearest evidence is for an increased risk of PD in people exposed to certain pesticides and a reduced risk in tobacco smokers. The pathology of the disease is characterized by the accumulation of a protein called alpha-synuclein into inclusions called Lewy bodies in neurons, and from insufficient formation and activity of dopamine produced in certain neurons within parts of the midbrain. Diagnosis of typical cases is mainly based on symptoms, with tests such as neuroimaging being used for confirmation. Modern treatments are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopamine neurons continue to be lost, a point eventually arrives at which these drugs become ineffective at treating the symptoms and at the same time produce a complication called dyskinesia, marked by involuntary writhing movements. Diet and some forms of rehabilitation have shown some effectiveness at alleviating symptoms. Surgery and deep brain stimulation have been used to reduce motor symptoms as a last resort in severe cases where drugs are ineffective. Research directions include a search of new animal models of the disease and investigations of the potential usefulness of gene therapy, stem cell transplants and neuroprotective agents. Medications to treat non-movement-related symptoms of PD, such as sleep disturbances and emotional problems, also exist. The disease is named after the English doctor James Parkinson, who published the first detailed description in An Essay on the Shaking Palsy in 1817. Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer's disease. Neuropathologically, it is characterized by the degeneration of populations of nerve cells that develop filamentous inclusions in the form of Lewy bodies and Lewy neurites. Recent work has shown that the filamentous inclusions of Parkinson's disease are made of the protein alpha-synuclein and that rare, familial forms of Parkinson's disease are caused by missense mutations in the alpha-synuclein gene. From: http://www.ncbi.nlm.nih.gov/pubmed/11193145 The main pathological characteristic of PD is cell death in the substantia nigra and more specifically the ventral part of the pars compacta, affecting up to 70% of the cells by the time the patient dies. The mechanisms by which the brain cells are lost are varied. One mechanism consists of an abnormal accumulation of the protein alpha-synuclein bound to ubiquitin in the damaged cells. This protein accumulation forms inclusions called Lewy bodies. According to the Braak staging Lewy bodies first appear in the olfactory bulb, medulla oblongata and pontine tegmentum, individuals at this stage being asymptomatic. As the disease evolves, Lewy bodies later attain the substantia nigra, areas of the midbrain and basal forebrain, and finally reach areas of the neocortex. From: http://en.wikipedia.org/wiki/Braak_staging Should we include 'idiopathic Parkinsons disease' (IPD) as a sub class or super class of Parkinsons disease?

ID

http://purl.obolibrary.org/obo/ND_0000139

comment

Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer's disease. Neuropathologically, it is characterized by the degeneration of populations of nerve cells that develop filamentous inclusions in the form of Lewy bodies and Lewy neurites. Recent work has shown that the filamentous inclusions of Parkinson's disease are made of the protein alpha-synuclein and that rare, familial forms of Parkinson's disease are caused by missense mutations in the alpha-synuclein gene. From: http://www.ncbi.nlm.nih.gov/pubmed/11193145

The main pathological characteristic of PD is cell death in the substantia nigra and more specifically the ventral part of the pars compacta, affecting up to 70% of the cells by the time the patient dies. The mechanisms by which the brain cells are lost are varied. One mechanism consists of an abnormal accumulation of the protein alpha-synuclein bound to ubiquitin in the damaged cells. This protein accumulation forms inclusions called Lewy bodies. According to the Braak staging Lewy bodies first appear in the olfactory bulb, medulla oblongata and pontine tegmentum, individuals at this stage being asymptomatic. As the disease evolves, Lewy bodies later attain the substantia nigra, areas of the midbrain and basal forebrain, and finally reach areas of the neocortex. From: http://en.wikipedia.org/wiki/Braak_staging

Should we include 'idiopathic Parkinsons disease' (IPD) as a sub class or super class of Parkinsons disease?

alternative term

idiopathic parkinsonism

paralysis agitans

Parkinson disease

Parkinson's

Parkinson's disease

primary parkinsonism

PD

Parkinsons

database_cross_reference

http://ontology.neuinfo.org/NIF/Dysfunction/NIF-Dysfunction.owl#birnlex_2098

definition editor

Alexander P. Cox

definition source

http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease.htm

http://en.wikipedia.org/wiki/Parkinson%27s_disease

label

Parkinsons disease

prefixIRI

ND:0000139

prefLabel

Parkinsons disease

textual definition

belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. (A disease characterized as a progressive motor disability manifested by tremors, shaking, muscular rigidity, and lack of postural reflexes. (PSY) * A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) (MSH) * progressive, degenerative disorder of the nervous system characterized by tremors, rigidity, bradykinesia, postural instability, and gait abnormalities; caused by a loss of neurons and a decrease of dopamine in the basal ganglia. (CSP) )

Parkinsons disease is a neurological disease where abnormal movement [tremor, rigidity, bradykinesia, postural instability] occurs resulting in a movement disorder caused by neurodegeneration as a result of death of dopaminergic cells in the substantia nigra. ---------- Parkinsons disease is a degenerative disorder of the central nervous system. It results from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain; the cause of cell-death is unknown. Early in the course of the disease, the most obvious symptoms are movement-related, including shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, cognitive and behavioural problems may arise, with dementia commonly occurring in the advanced stages of the disease. Other symptoms include sensory, sleep and emotional problems. PD is more common in the elderly with most cases occurring after the age of 50. The main motor symptoms are collectively called parkinsonism, or a "parkinsonian syndrome". Parkinson's disease is often defined as a parkinsonian syndrome that is idiopathic (having no known cause), although some atypical cases have a genetic origin. Many risk and protective factors have been investigated: the clearest evidence is for an increased risk of PD in people exposed to certain pesticides and a reduced risk in tobacco smokers. The pathology of the disease is characterized by the accumulation of a protein called alpha-synuclein into inclusions called Lewy bodies in neurons, and from insufficient formation and activity of dopamine produced in certain neurons within parts of the midbrain. Diagnosis of typical cases is mainly based on symptoms, with tests such as neuroimaging being used for confirmation. Modern treatments are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopamine neurons continue to be lost, a point eventually arrives at which these drugs become ineffective at treating the symptoms and at the same time produce a complication called dyskinesia, marked by involuntary writhing movements. Diet and some forms of rehabilitation have shown some effectiveness at alleviating symptoms. Surgery and deep brain stimulation have been used to reduce motor symptoms as a last resort in severe cases where drugs are ineffective. Research directions include a search of new animal models of the disease and investigations of the potential usefulness of gene therapy, stem cell transplants and neuroprotective agents. Medications to treat non-movement-related symptoms of PD, such as sleep disturbances and emotional problems, also exist. The disease is named after the English doctor James Parkinson, who published the first detailed description in An Essay on the Shaking Palsy in 1817.

subClassOf

http://purl.obolibrary.org/obo/ND_0000068

Delete Subject Author Type Created
No notes to display
Create mapping

Delete Mapping To Ontology Source
http://purl.obolibrary.org/obo/ND_0000139 NDDO SAME_URI
urn:agi-folder:parkinson's_disease BPT LOOM
http://purl.obolibrary.org/obo/ND_0000139 NDDO LOOM
http://purl.obolibrary.org/obo/DOID_14330 FRMO LOOM
http://purl.obolibrary.org/obo/DOID_14330 DTO LOOM
http://purl.obolibrary.org/obo/DOID_14330 DOID LOOM
http://purl.obolibrary.org/obo/DOID_14330 BAO LOOM
http://purl.obolibrary.org/obo/DOID_14330 HHEAR LOOM
http://purl.obolibrary.org/obo/DOID_14330 DDSS LOOM
http://purl.obolibrary.org/obo/DOID_14330 ODAE LOOM
http://purl.obolibrary.org/obo/DOID_14330 NIFSTD LOOM
http://purl.obolibrary.org/obo/DOID_14330 MIDO LOOM
http://purl.obolibrary.org/obo/DOID_14330 FNS-H LOOM
http://www.projecthalo.com/aura#Parkinsons-Disease AURA LOOM
http://purl.bioontology.org/ontology/ICD10/G20 ICD10 LOOM
http://purl.bioontology.org/ontology/ICPC2P/N87001 ICPC2P LOOM
http://purl.bioontology.org/ontology/LNC/LP75351-4 LOINC LOOM
http://www.co-ode.org/ontologies/galen#ParkinsonsDisease GALEN LOOM
http://www.ebi.ac.uk/efo/EFO_0002508 CLO LOOM
http://purl.bioontology.org/ontology/CSP/2057-3689 CRISP LOOM
http://www.owl-ontologies.com/NPOntology.owl#DOID_14330 NATPRO LOOM
http://www.semanticweb.org/cjf/ontologies/2022/8/NeuralReprogrammingOntology(NRO)#Parkinson's_disease NRO LOOM
http://purl.bioontology.org/ontology/RCD/F12.. RCD LOOM
http://nanbyodata.jp/ontology/NANDO_1200010 NANDO LOOM
http://purl.org/obo/owl/DOID#DOID_14330 HUPSON LOOM
http://uri.neuinfo.org/nif/nifstd/birnlex_2098 NIFDYS LOOM
http://uri.neuinfo.org/nif/nifstd/birnlex_2098 NIFSTD LOOM
http://bioontology.org/projects/ontologies/birnlex#birnlex_2098 BIRNLEX LOOM
http://purl.bioontology.org/ontology/MEDDRA/10061536 MEDDRA LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#C0030567 OCHV LOOM
http://www.semanticweb.org/emif/ontologies/2015/AD/RCwPMO5ludc6HDuMnSWh7R EMIF-AD LOOM
http://purl.obolibrary.org/obo/NCIT_C26845 BERO LOOM
http://purl.bioontology.org/ontology/ICD10CM/G20 ICD10CM LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/49049000 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/LNC/MTHU020807 LOINC LOOM
http://purl.obolibrary.org/obo/Parkinsons_Disease NND_ND LOOM
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Parkinson_s_Disease CSEO LOOM
http://purl.bioontology.org/ontology/RCTV2/F12..00 RCTV2 LOOM
http://ontology.apa.org/apaonto/termsonlyOUT%20(5).owl#Parkinson's_Disease APANEUROCLUSTER LOOM
http://ontology.apa.org/apaonto/termsonlyOUT%20(5).owl#Parkinson's_Disease APADISORDERS LOOM
http://ontology.apa.org/apaonto/termsonlyOUT%20(5).owl#Parkinson's_Disease APAONTO LOOM
http://purl.bioontology.org/ontology/LNC/LA27533-1 LOINC LOOM
http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease NEUROBRG LOOM
http://purl.bioontology.org/ontology/ICD9CM/332 ICD9CM LOOM